Replimune challenges Iovance
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
ASCO 2024 movers – Affimed wins, Caribou loses
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
ASCO 2024 – AstraZeneca’s GPC3 secret sauce
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
The group is keeping faith with the novel target KLK2.
